BioDelivery Provides Corporate Update And Reports Third Quarter 2016 Financial Results
Six BUNAVAIL® Managed Care Agreements Secured Since July; Additional Access to BUNAVAIL Provides Potential for Strong First Half 2017 Growth
Department of Health and Human Services Increases Patient Cap; Potential for Significant Increase in Patients Entering Treatment for Opioid Dependence
BDSI Meets Third Quarter Objective of Providing Stability to BUNAVAIL Prescription Sales Following Second Quarter Commercial Consolidation
BUNAVAIL Prescription Sales Up 68% Compared to Third Quarter 2015
Top-Line Phase 2b Data for Clonidine Topical Gel Expected in December
Buprenorphine 30-Day Injection IND Submission Expected by Year-End
Department of Health and Human Services Increases Patient Cap; Potential for Significant Increase in Patients Entering Treatment for Opioid Dependence
BDSI Meets Third Quarter Objective of Providing Stability to BUNAVAIL Prescription Sales Following Second Quarter Commercial Consolidation
BUNAVAIL Prescription Sales Up 68% Compared to Third Quarter 2015
Top-Line Phase 2b Data for Clonidine Topical Gel Expected in December
Buprenorphine 30-Day Injection IND Submission Expected by Year-End